EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MET Enhances Amivantamab Binding to EGFR and Antibody‐Dependent Cellular Toxicity

Shigeki Sato iD, Neval Yilmaz, Sachiko Arai, Katsuya Sakai, Hiroki Sato, Yuya Murase iD, Tsukasa Ueda, Hayato Koba, Shigeki Nanjo, Yuichi Tambo, Hiroshi Kotani iD, Koji Fukuda iD und 6 weitere

Cancer Science · 2026-01 · 117 (1) · 118-129

DOI: 10.1111/cas.70228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 09.11.2025. Verfasst von Shigeki Sato und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibody-Dependent Cell Cytotoxicity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Pharma, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amivantamab is a bispecific antibody against epidermal growth factor receptor (EGFR) and MET that has been approved for nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations and common EGFR mutations, such as exon 19 deletion and L858R. MET has attracted attention as a therapeutic target for lung cancer; however, its role in EGFR binding and amivantamab‐induced antibody‐dependent cellular toxicity (ADCC) remains unclear. We used high‐speed atomic force microscopy (HS‐AFM) to observe the real‐time binding of amivantamab to the EGFR‐extracellular domain (ECD) and MET‐ECD and visualized the binding of amivantamab to the EGFR domain 3 and MET Sema domain. Furthermore, we observed the trimer comprising amivantamab bound to EGFR and MET. Western blot analysis of the gel filtration fractions revealed that the MET‐ECD enhanced the binding of amivantamab to the EGFR‐ECD, which promoted trimer formation. Moreover, amivantamab‐induced mononuclear cell‐mediated ADCC in NSCLC cells with common EGFR mutations. ADCC activity was positively correlated with EGFR expression in tumor cells. Studies using MET‐knockout NSCLC cells revealed that MET enhanced ADCC activity with low concentrations of amivantamab. Thus, MET augments amivantamab binding to EGFR and augments ADCC activity at low amivantamab concentrations. These results indicate that binding to MET contributes to the increased efficacy of amivantamab in NSCLC with common EGFR mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metCarcinoma, Non-Small-Cell LungLung NeoplasmsAntibody-Dependent Cell CytotoxicityAntibodies, BispecificHumansErbB ReceptorsCell Line, TumorMutationProtein Binding

Stichwörter der Autor:innen

AFMAmivantamabEGFRMETbispecific antibody

Substanzen

ErbB ReceptorsProto-Oncogene Proteins c-metEGFR protein, humanMET protein, humanamivantamabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
  • Division of Innovative Cancer Control Research, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
  • Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
  • Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
  • Department of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
  • Division of Genome Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

ORCID-Profile: Shigeki Sato, Yuya Murase, Hiroshi Kotani, Koji Fukuda, Kunio Matsumoto, Seiji Yano

Förderung

  • Janssen Pharma
  • Japan Society for the Promotion of Science

Zitieren

APA

Sato, S., Yilmaz, N., Arai, S., Sakai, K., Sato, H., Murase, Y., Ueda, T., Koba, H., Nanjo, S., Tambo, Y., Kotani, H., Fukuda, K., Taniguchi, H., Amyot, R., Flechsig, H., Isozaki, H., Matsumoto, K., & Yano, S. (2026). MET Enhances Amivantamab Binding to EGFR and Antibody‐Dependent Cellular Toxicity. Cancer Science, 117(1), 118-129. https://doi.org/10.1111/cas.70228

Vancouver

Sato S, Yilmaz N, Arai S, Sakai K, Sato H, Murase Y, et al. MET Enhances Amivantamab Binding to EGFR and Antibody‐Dependent Cellular Toxicity. Cancer Science. 2026;117(1):118-129. doi:10.1111/cas.70228

BibTeX
@article{Sato2026,
  author = {Sato, Shigeki and Yilmaz, Neval and Arai, Sachiko and Sakai, Katsuya and Sato, Hiroki and Murase, Yuya and Ueda, Tsukasa and Koba, Hayato and Nanjo, Shigeki and Tambo, Yuichi and Kotani, Hiroshi and Fukuda, Koji and Taniguchi, Hiroaki and Amyot, Romain and Flechsig, Holger and Isozaki, Hideko and Matsumoto, Kunio and Yano, Seiji},
  title = {MET Enhances Amivantamab Binding to EGFR and Antibody‐Dependent Cellular Toxicity},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {1},
  pages = {118--129},
  doi = {10.1111/cas.70228}
}
Kostenlos starten →